Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients

•Uncommon EGFR mutations exhibit favorable but inconsistent treatment responses and survival outcomes to gefitinib and erlotinib.•Patients with compound EGFR mutations, especially those containing 19 deletion or L858R, had superior response and survival benefits compared to those with single uncommon EGFR mutation.•Gefitinib showed a superior tumor response advantage and PFS benefit compared to erlotinib in the treatment of patients with uncommon EGFR mutations.